spacer
home > epc > autumn 2008 > hit the mark
PUBLICATIONS
European Pharmaceutical Contractor

Hit the Mark

Increasing pressure is being placed on the pharmaceutical industry to limit the costs and time associated with delivering a drug to the market. First-in-human and other early phase studies are a critical step in the complex process. Normally limited to objectives based around pharmacokinetics, safety and tolerability, early phase studies provide an underutilised opportunity to obtain valuable pharmacodynamic data regarding a drug’s mechanism of action, pharmacological activity and potential dosing regimens. Carefully chosen biomarkers are able to be easily incorporated into early phase drug studies and provide guidance for important decisions concerning a drug’s future.

Analyses show that the largest part of the development costs are spent on failures, particularly in the latter part of the process because of the high costs of large-scale clinical trials (1,2). Consequently, there is much pressure on the drug development process to ‘kill failures early’ by showing that the compound does not have the characteristics of a proper drug – or vice versa – and preferably to show that it does (3). Thus, drug development has become a much more continuous process than is suggested by the ‘classic’ separation into distinct phases. In fact, modern ICH guidelines, as implemented by the regulatory authorities, stipulate the intelligent use of pharmacodynamic drug effect measurements during all stages of development (4-6).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Joop van Gerven is Director of CNS Studies at CHDR. Joop studied English and Medicine at Utrecht University. After obtaining his MD in 1984, he worked in the Department of Internal Medicine of Leiden University Medical Center (LUMC). In 1990 he completed a PhD thesis on aldose reductase inhibitor treatment in diabetes mellitus. He was trained as a Neurologist in Dijkzigt University Hospital in Rotterdam from 1988 to 1994. During that period, he was also a consultant for Wyeth on diabetic complications. Since 1994 he has been responsible for CNS research at CHDR in Leiden, and is responsible for consultancy and research on central nervous system drugs and methods. He is also active clinically as a Consultant Neurologist at LUMC. In 2004 he was appointed Professor of Clinical Psychoneuropharmacology at Leiden University.

Justin Hay is Senior Clinical Scientist, CNS Studies at CHDR. Justin completed his BSc (Biomed Science) with majors in Pharmacology, Microbiology & Immunology (2001) and graduated with First Class Honours (2002). In 2007 he was conferred his PhD in Pharmacology from the University of Adelaide, Australia. His thesis investigated the pain sensitivity of chronic opioid users. Since March 2007, Justin has held his current position, where he is investigating how pain tests can be used as a screening tool in early drug development.

spacer
Professor Joop van Gerven
spacer
spacer
spacer
Justin Hay
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Entry now open for the PPMA Group Industry Awards 2019

The 2019 PPMA Group Industry Awards will be held at the National Conference Centre (NEC), Birmingham, on the evening of the first day of the PPMA Total Show 2019 – Tuesday, 1 October 2019. 
More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement